It is currently be researched in the treatment of epithelial ovarian cancer-see the external link to the clinical trial MIMOSA (Monoclonal antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab).
It is currently be researched in the treatment of epithelial ovarian cancer. Abagovomab has been developed by the pharmaceutical company Menarini, which recently started a multicenter clinical trial, internationally known as MIMOSA (Monoclonal antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab).